The FDA’s Commissioner’s National Priority Voucher (CNPV) Pilot Program, launched in June 2025, creates a highly accelerated 1–2 month review pathway for products addressing key national health priorities such as unmet medical needs, domestic manufacturing resiliency, public health threats, healthcare affordability, and advanced therapeutic innovation. Entry into the program may occur through FDA nomination or a brief sponsor- submitted application.
White Paper
Commissioner’s National Priority Voucher (CNPV) Pilot Program
Related Resources
All Resources
post
How Long Does FDA Approval Take After Phase 3?
Read More
post
Pitfalls to Avoid in Late-Stage Pharmaceutical Development (and How to Prevent Costly Delays)
Read More
post
What Are the 4 Stages of Drug Development?
Read More
white-paper
The Potential Impact of U.S. Tariffs on the Biotech Sector: Manufacturing, Funding, and Clinical Trials
Read More
Let's move from science to success.
Let’s Talk